Citations

Clear

4510 citation(s) found for "Scott, C".

Predicted versus observed outcomes in the ALT-FLOW early feasibility study
Fioretti, Francesco , Gray, William A, Hibbert, B, Lindenfeld, JoAnn, Tedford, Ryan J, Zahr, Firas, Butler, Javed , Butler, Javed , Gray, William A. , Hibbert, Benjamin , Lindenfeld, JoAnn , Tedford, Ryan J. , Zahr, Firas

Mayo Clinic

ESC Heart Failure | April 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag101 | PMID 42257333 Get It

Abstract Background and Aims Whether hemodynamic and symptomatic benefits of the APTURE left atrial-to-coronary sinus shunt translate into clinical outcome benefit in heart failure with left ventricular ejection fraction >40% remains unknown. Methods In this post hoc analysis of ALT-FLOW EFS patients undergoing APTURE implantation, Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score-predicted 1-year all-cause mortality was compared with observed mortality by Kaplan-Meier analysis of adjudicated events. Heart failure hospitalization (HFH) rates were compared for the 12 months before vs after implantation. Additional analyses included stratification by baseline sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and N-terminal pro-B-type natriuretic peptide (NT-proBNP), recurrent HFH cumulative hazard estimation (Nelson-Aalen), and H2FPEF score calculation. Results Among 95 patients (mean age 70.9 ± 8.5 years; 50% women; 93% New York Heart Association Class III; 85.9% with H2FPEF score >3), MAGGIC-predicted 1-year mortality was 13.0%. Observed 1-year survival was significantly higher than predicted (94.7% vs 87.0%; P=0.04), consistent across SGLT2i subgroups (log-rank P=0.59). The proportion of patients with HFH declined from 37.9% pre implantation to 9.6% post implantation (P<0.0001), with event rates falling from 0.61 to 0.21 per patient-year (P<0.001) and a 1-year cumulative hazard of recurrent HFH of 0.19 (95% confidence interval, 0.12-0.31). HFHs were evenly distributed across NT-proBNP strata. Conclusions In ALT-FLOW EFS, observed 1-year mortality was lower than MAGGIC-predicted mortality, and post implantation HFH rates were lower than pre implantation rates. These hypothesis-generating findings will require confirmation in the randomized, sham-controlled ALT-FLOW II trial.
Abstract 7599: HOUSES as a screening tool for cancer screening: Patient-level housing-based socioeconomic status and breast and cervical cancer screening adherence.
Park, Eunice , Beenken, Madison, Watson, Dave , Wi, Chung I., Haddad, Tufia C. , Asiedu, Gladys B. , Flock, Carolyn R., Lynch, Brian , Odedina, Folakemi, Okuno, Scott H. , Juhn, Young J. , Wi, Chung‐Il , Ballman, Karla V. , Cerhan, James R.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7599-7599

10.1158/1538-7445.am2026-7599 Get It

Abstract Introduction: The National Cancer Institute estimated almost 317,000 new breast cancer and over 13,000 new cervical cancer cases in 2025. While the National Breast and Cervical Cancer Early Detection Program has served millions of women over the past two decades, inequities in cancer screening, subsequently delayed diagnosis, and timely and appropriate treatment remain a public health challenge in the United States. Despite the substantial impact of social determinants of health (SDOH) on cancer screening, few studies have accounted for SDOH at the individual level when assessing breast and cervical cancer screening adherence. The primary objective of this study is to examine whether the individual-level SDOH, measured using HOUsing-based SocioEconomic Status (HOUSES) index, is associated with breast and cervical cancer screening non-adherence (not current on respective USPSTF recommendations for age and frequency). Methods: In this retrospective study, patients were identified as those receiving primary care in the Mayo Clinic Health System and Mayo Clinic (Rochester, MN). The Midwest Quality Metrics panel was then used to assess patients due for screening for breast or cervical cancer in July 2023. The HOUSES, using home address and publicly available data on the residence which measures and categorizes housing status into quartiles, was obtained using the electronic health records (EHRs)-linkable patient-level information. Logistic regression analyses were conducted, controlling for Census block group-level adverse social exposome from the Area Deprivation Index, age, and comorbidities. Results are presented as odds ratios (OR) with corresponding 95% confidence intervals (CI). Results: For breast cancer, among 128,462 eligible patients, 20.1% (n= 25,857) were non-adherent. Compared to the highest HOUSES quartile (Q4), lower HOUSES groups showed significantly higher odds of non-adherence: Q3 OR=1.20 (95% CI=1.15, 1.25), Q2 OR=1.45; (95% CI=1.40, 1.53), and Q1 OR=1.90 (95% CI=1.81, 1.99). For cervical cancer, among 175,712 eligible patients, 29.9% (n=52,533) were non-adherent. Compared to the highest HOUSES quartile (Q4), lower HOUSES groups showed significantly higher odds of non-adherence: Q3 OR=1.07 (95% CI=1.03, 1.10), Q2 OR=1.16; (95% CI=1.12, 1.20), and Q1 OR=1.36 (95% CI=1.31, 1.41). Conclusions: A clinically meaningful association between the HOUSES index and cancer screening adherence was observed. A lower HOUSES index was associated with higher odds of non-adherence for both breast and cervical cancer screening, even after accounting for neighborhood-level risk, age, and comorbidities. Incorporating HOUSES into EHRs can be a practical “screening-for-screening” tool that enables close monitoring of higher-risk patients without additional burden of surveys. Citation Format: Eunice Y. Park, Madison Beenken, Dave Watson, Chung Il Wi, Tufia Haddad, Gladys Asiedu, Karla BALLMAN, James R. Cerhan, Carolyn Flock, Brian Lynch, Folakemi T. Odedina, Scott H. Okuno, Young J Juhn, . HOUSES as a screening tool for cancer screening: Patient-level housing-based socioeconomic status and breast and cervical cancer screening adherence [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7599.
Abstract 2779: Development and evaluation of a MIRAI 5-year risk model with a breast cancer polygenic risk score.
Scott, C, Kraft, Peter, Banerjee, Imon, Medero, Ramon Correa, Couch, Fergus J., Vachon, Celine M., Scott, Christopher G. , Banerjee, Imon , Correa, Ramón , Norman, Aaron D. , Couch, Fergus J. , Kerlikowske, Karla , Winham, Stacey J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2779-2779

10.1158/1538-7445.am2026-2779 Get It

Abstract Artificial intelligence (AI)-scores estimated from digital mammograms predict future breast cancer (BC) risk. MIRAI is a deep learning BC risk model that provides a continuous 5-year risk of overall BC from four screening full field digital mammograms. Common germline genetic variation in the form of a polygenic risk score (BC-PRS) is associated with increased BC risk and may improve MIRAI’s 5-year risk prediction. Our goal was to develop an updated MIRAI 5-year risk model that incorporates the BC-PRS (MIRAI+PRS) and to evaluate its discriminatory accuracy and calibration for both overall and invasive BC compared to MIRAI alone. We developed the MIRAI+PRS model by multiplying each woman’s 5-year MIRAI risk estimate by their relative risk based on their BC-PRS relative to the population mean. We evaluated the models within the Mayo Clinic Biobank mammography cohort, comprised of 12,307 women without a prior history of BC; 176 invasive and 250 overall BC were diagnosed within 5 years. MIRAI was estimated on screening mammograms closest to enrollment but at least 6 months prior to BC. Discriminatory accuracy, assessed by C-statistic, was high and similar for MIRAI+PRS vs. MIRAI models, for overall BC and invasive BC (Table). Calibration assessed by observed to expected (O/E) ratios was also similar for MIRAI+PRS compared to MIRAI predictions for BC outcomes (Table), although there was improvement in decile-specific O/E ratios across the lowest risk deciles (<1.67%) for MIRAI+PRS. Calibration for invasive cancer was poor for MIRAI with or without PRS. In summary, the MIRAI+PRS risk model did not result in significant difference of discriminatory accuracy or overall calibration compared to the MIRAI model, but there was evidence for improved calibration for women with 5-year risk below 1.67%. For invasive BC, the model had poor calibration regardless of whether PRS was included, underscoring the importance of training AI models for BC outcomes that are associated with a clinical intervention. Citation Format: Christopher G. Scott, Peter Kraft, Imon Banerjee, Ramon Correa Medero, Aaron D. Norman, Fergus J. Couch, Karla Kerlikowske, Stacey J. Winham, Celine M. Vachon. Development and evaluation of a MIRAI 5-year risk model with a breast cancer polygenic risk score [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2779.
Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials
Rodriguez-Riascos, Juan F., Navale, Dravid, Somappa, Aakash , Mendizabal, Ricardo Estrada, Scott, Luis R., Shen, Win-Kuang, Srivathsan, Komandoor , Estrada-Mendizábal, Ricardo J. , Rodriguez, Juan F. , Rodriguez-Riascos, Juan F , Estrada-Mendizabal, Ricardo J , Scott, Luis R , Shen, Win-Kuang , Srivathsan, Komandoor , Scott, Luis R.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 3, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circep.125.014692 | PMID 41930400 Get It

BACKGROUND: Catheter ablation for atrial fibrillation is a widely used rhythm-control strategy, yet its role in reducing thromboembolic risk and enabling oral anticoagulation (OAC) discontinuation remains uncertain. This meta-analysis aims to comprehensively synthesize and evaluate randomized controlled trial evidence supporting long-term antithrombotic strategies in patients with atrial fibrillation undergoing catheter ablation. METHODS: A systematic literature search was performed in MEDLINE/PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials evaluating antithrombotic strategies after catheter ablation for atrial fibrillation. The primary outcome was ischemic stroke. A frequentist network meta-analysis comparing reported treatment arms, along with a pooled incidence meta-analysis for outcomes of interest, was conducted. RESULTS: Four randomized controlled trials, including 3924 patients, met the inclusion criteria. Three trials compared long-term OAC continuation versus OAC discontinuation, and 1 compared OAC continuation with left atrial appendage occlusion after catheter ablation. No significant differences in stroke incidence were observed when comparing OAC or left atrial appendage occlusion with no antithrombotic therapy (incidence rate ratio, 0.90 [95% CI, 0.02–33.85]; P =0.95; incidence rate ratio, 0.79 [95% CI, 0.00–241.01]; P =0.94, respectively). Among patients who discontinued antithrombotic therapy without undergoing left atrial appendage occlusion (n=1161), with 2864 cumulative person-years of follow-up, the pooled incidence of stroke was 0.23 events per 100 person-years (95% CI, 0.02–2.43; I 2 =0%). CONCLUSIONS: This analysis reinforces that, across randomized data, the incidence of thromboembolic events in patients who discontinued OAC after successful ablation remained low. However, the evaluation of net clinical benefit is limited by the low number of events across all treatment arms, underscoring the need for larger studies with prolonged follow-up to further validate the safety of this strategy, particularly in higher-risk populations.
Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.
Tran, Nguyen H., Hirdler, Jacob, Antony, Ajith , Torbenson, Michael S., Thompson, Scott M. , Halfdanarson, Thor R., Jin, Zhaohui, Fonkoua, Lionel Aurelien Kankeu, Washburn, Leslie, Revzin, Alexander , Dong, Haidong, Jatoi, Aminah , Borad, M., Bekaii-Saab, T., Gores, Gregory J., Roberts, Lewis R. , Johnson, Geoffrey B., Goenka, Ajit H. , Roberts, Lewis R , Tran, Nguyen H. , Hirdler, Jacob B. , Teske, Jacob J. , Venkatesh, Sudhakar K. , Mahipal, Amit , Torbenson, Michael , Halfdanarson, Thor R, Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , McWilliams, Robert R. , Babiker, Hani M. , Borad, Mitesh J. , Gores, Gregory J. , Johnson, Geoffrey B

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2611-2611

10.1158/1538-7445.am2026-2611 Get It

Abstract Prostate-specific membrane antigen (PSMA) is highly expressed in tumor-associated neovasculature in hepatocellular carcinoma (HCC), highlighting its promise as a theranostic target. This prospective study aimed to evaluate the utility of novel biomarkers derived from PSMA positron emission tomography computed tomography (PET/CT) to assess treatment response in advanced HCC patients (pts) receiving first line immune checkpoint inhibitors (ICI). Methods: This study (NCT05176223) enrolled unresectable, advanced HCC pts eligible for first-line ICI (atezolizumab/bevacizumab [A/B] or durvalumab/tremelimumab [D/T]) with measurable disease according to RECIST criteria. Primary endpoints: progression-free survival (PFS) per RECIST 1.1 and mRECIST; overall survival (OS); and best overall response. The survival distribution was estimated using the Kaplan-Meier method. Observed agreement is defined as the proportion of pts whose responses, as classified by PET/CT or CT, were concordant. Weighted kappa and Cohen’s kappa were used to quantify the strength of agreement between PET/CT and CT. Pts completed up to five 68Ga-PSMA PET/CT scans and blood collections. Results: Twenty-six pts were enrolled (25 evaluable) between Oct 2022 and Nov 2024. Median follow up was 22.1 months (m) (Q1, Q3: 14.5-23.7). Median age 68 yrs, 72% male, 88% White, 68% Child-Pugh [CP] A, 32% CP B, 32% Barcelona Clinic Liver Cancer [BCLC] stage B, 68% BCLC stage C, 36% with microvascular invasion; 56% received A/B and 40% received D/T treatment. PSMA was positive in 96% of pts at baseline with median SUVmax 14.3 (range 5.1-40.5) and median background liver SUVmax 3.9 (range 2.1-6.8). Median (95%CI) PFS was 5.6 m (4.6-12.5) by both RECIST and mRECIST. Median (95%CI) OS was 18.6 m (7.2-not estimable), with 56% deceased. The observed agreement between PET/CT adapted PERCIST criteria compared to RECIST and mRECIST in determining the best response was 46% and 50% and weighted kappa of 0.63 (95% CI: 0.37-0.90) and 0.66 (0.41-0.92), respectively. Observed agreement between PERCIST compared to RECIST and mRECIST for responders’ assessment was 67% and 71% with Cohen’s kappa of 0.36 (0.03-0.68) and 0.43 (0.11-0.76), respectively. Conclusion: In this cohort, PSMA PET/CT avidity was observed in all but one pt with advanced HCC, each demonstrating moderate to high SUVmax values. Median OS and PFS were consistent with outcomes reported in clinical trials. Response assessment using 68Ga-PSMA PET/CT according to PERCIST criteria showed good concordance with both RECIST and mRECIST standards. Analysis of immune biomarkers is ongoing. Citation Format: Nguyen H. Tran, Jacob Hirdler, Ajith Antony, Jacob Teske, Sudhakar K. Venkatesh, Amit Mahipal, Michael S. Torbenson, Scott M. Thompson, Thor R. Halfdanarson, Zhaohui Jin, Lionel Aurelien Kankeu Fonkoua, Leslie A. Washburn, Alexander Revzin, Haidong Dong, Robert R. Mcwilliams, Aminah Jatoi, Hani M. Babiker, Mitesh J. Borad, Tanios Bekaii-Saab, Gregory J. Gores, Lewis R. Roberts, Geoffrey B. Johnson, Ajit H. Goenka. Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2611.
Abstract 405: (Z)-endoxifen modulates estrogen receptor and cell-cycle signaling to induce synergistic antiproliferative effects with CDK4/6 inhibition in endometrial cancer models.
Choong, Grace M. , Hou, X, Hammer, S. S., Blackburn, Scott, Weroha, S. John , Quay, Steven C., Hammer, Sandra S. , Quay, Steven C.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 405-405

10.1158/1538-7445.am2026-405 Get It

Abstract Background: Endometrial cancer (EC) remains a major gynecologic malignancy driven in part by aberrant estrogen receptor (ER) signaling. The active tamoxifen metabolite (Z)-endoxifen exhibits dual SERM/SERD-like activity, modulating ER function while exerting additional noncanonical antiproliferative effects. Understanding (Z)-endoxifen’s mechanisms of action and its interaction with cell-cycle regulators is critical to optimizing targeted therapy in EC. This study investigated the molecular and functional effects of (Z)-endoxifen, alone and in combination with the CDK4/6 inhibitor abemaciclib, across diverse EC models to define mechanistic activity and translational potential. Methods: ER+ (Ishikawa, HCI-EC23, patient derived organoid U1561.005) and ER-variable (ARK1, ARK2) EC models were treated with estrogen (0-10 nM), (Z)-endoxifen (125 nM-10 µM) or fulvestrant (0-2.5 μM), and abemaciclib (0-10 μM), as single agents or in combination. Cell viability was assessed using luminescence-based assays. Dose-response analyses and combinatorial synergy were evaluated to determine endocrine sensitivity, ER dependency, and downstream cell-cycle effects. Results: Estrogen induced biphasic proliferative responses in ER+ models, confirming ligand-driven mitogenic signaling. (Z)-Endoxifen monotherapy suppressed viability across all cell lines, demonstrating superior potency to fulvestrant and activity independent of ER expression status. Mechanistically, (Z)-endoxifen abrogated estrogen-induced proliferative peaks, consistent with ER antagonism and potential receptor degradation, while also exerting ER-independent effects suggestive of cell-cycle modulation. Abemaciclib monotherapy inhibited viability in both ER+ and ER− models, and its combination with (Z)-endoxifen yielded strong synergistic activity (Chou-Talalay combination index < 1), including in ER-negative ARK2 and the ER+ U1561.005 organoid. This synergy likely arises from concurrent disruption of ER signaling and CDK4/6-cyclin D regulatory pathways. Conclusions: (Z)-Endoxifen demonstrates dual ER-dependent and ER-independent activity in EC preclinical models. Synergy was observed in combination a CDK 4/6 inhibitor. These findings broaden the current understanding of (Z)-endoxifen’s efficacy and support further exploration of its potential therapeutic role in ER-driven and mixed-phenotype EC, including evaluation of responses across ER expression levels. Citation Format: Grace Choong, Xiaonan Hou, Sandra Suarez Hammer, Scott M. Blackburn, John Weroha, Steven C. Quay. (Z)-endoxifen modulates estrogen receptor and cell-cycle signaling to induce synergistic antiproliferative effects with CDK4/6 inhibition in endometrial cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 405.
The management of hepatorenal syndrome–acute kidney injury (HRS-AKI): A national survey of hepatology provider practices
Chandna, Shaun , Lee, Brian T. , Aby, Elizabeth S. , Izzy, Manhal , Sherman, Courtney B. , Aron, Joshua, Luther, Jay , GOEL, A. B., Rice, J. E., Chen, Po‐Hung , Asrani, Sumeet, Lizaola-Mayo, Blanca, Elfeki, Mohamed, Wong, Florence, Biggins, Scott W. , Garcia-Tsao, Guadalupe, Singal, Ashwani K., Elfeki, Mohamed A. , Elfeki, Mohamed A , Cullaro, Giuseppe , Im, Gene , Simonetto, Douglas A. , Gonzalez, Stevan A , Goel, Aparna, Jophlin, Loretta , Rice, John, Asrani, Sumeet K. , Lizaola‐Mayo, Blanca , Wong, Florence , García–Tsao, Guadalupe , Singal, Ashwani K.

Mayo Clinic

Hepatology Communications | April 1, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000905 | PMID 41921139 Get It

Background: Hepatorenal syndrome–acute kidney injury (HRS-AKI) is associated with high mortality in cirrhosis. Recent FDA approval of terlipressin and updated clinical guidance have expanded management options, but real-world practice patterns remain unknown. Methods: We conducted a nationwide survey of U.S. hepatology providers regarding HRS-AKI management practices. The 33-question survey assessed provider demographics, vasoconstrictor selection, treatment timing, and adherence to guideline recommendations. Results: Among 162 respondents, most were hepatologists (94%) at academic centers (83%). Only 11% obtained a nephrology consultation at AKI detection, with 44% waiting until worsening renal function. Terlipressin was available at 80% of institutions but more commonly at academic centers (84% vs. 53%, p =0.003). Consistent with guideline recommendations, 77% of providers initiate vasoconstrictors only after completing a trial of volume expansion (if no renal improvement), particularly in academic centers (80% vs. 60% non-academic, p =0.03). Terlipressin (49%) and midodrine/octreotide (44%) were preferred first-line treatments, with providers at academic centers more likely to use midodrine/octreotide (46% vs. 30%, p =0.008). Mean arterial pressure was used by 62% of providers to guide vasoconstrictor dosing. Most providers (73%) discontinued vasoconstrictor treatment after 4 days if no improvement. Conclusions: Significant variations exist between guideline recommendations and real-world HRS-AKI management, especially first-line treatment choice, treatment monitoring, and nephrology consultation. These findings highlight opportunities to improve guideline implementation and identify areas where practice patterns might inform provider education and future guidance updates.
Detecting Uniformity Artifacts in Ultrasound Transducers
Gu, Chunming , Brom, Kevin M. , Stekel, Scott F. , Tradup, Donald J., Xin, Zhuoyao, Hangiandreou, Nicholas J., Dave, Jaydev , Long, Zaiyang , Brom, Kevin, Stekel, Scott, Dave, Jaydev K.

Mayo Clinic

Journal of Ultrasound in Medicine | April 1, 2026 | Volume: 45 | Issue: 9 | Pages: 1889-1896

10.1002/jum.70239 | PMID 41919451 Get It

Objectives Uniformity artifacts caused by defective transducer elements or scanner malfunctions degrade diagnostic image quality. Traditional quality control (QC) methods, such as phantom testing and visual or quantitative image analysis, can be labor‐intensive and limited in test frequency. This study aims to develop a deep learning framework to detect uniformity artifacts and complement traditional QC. Methods Clinical median images were generated by aggregating co‐registered grayscale ultrasound images acquired by each transducer and computing median intensity values across the image stack. A pretrained ResNet‐18 model was fine‐tuned on a dataset consisting of clinical median images from linear and curvilinear transducers. The dataset was divided into training, validation, and testing subsets, ensuring no overlap between training and test transducers. To assess generalizability, the model was also evaluated on an independent test set of 396 phantom‐validated images from linear and curvilinear transducers. Results The model achieved 100% accuracy on the first dataset's test set. On the independent test set, it attained 87.4% accuracy with high sensitivity (0.84) and specificity (0.88), demonstrating robust generalization. Occlusion sensitivity maps confirmed the model's attention to uniformity artifact regions. Conclusion The deep learning framework using clinical median images demonstrated robust performance across several linear and curvilinear transducer models. It could be integrated into the clinical QC workflow by automating artifact detection in an effective and timely manner. In our practice, it can flag median images classified as artifact‐present, reducing human review time by approximately 80% while preserving detection accuracy.